-

Surmodics to Present at Sidoti & Company Virtual Investor Conference

Webcast is Live on Wednesday, January 19, at 10:45 a.m. (ET)

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj, president and chief executive officer, and Tim Arens, senior vice president of finance and chief financial officer, will present and host one-on-one meetings with investors at the Sidoti Winter Virtual Investor Conference on Wednesday, January 19, 2022. A live audio webcast of the presentation will be available by going to the investor relations portion of the Company’s website at https://surmodics.gcs-web.com, under the events and presentations subcategory. The presentation will begin at 10:45 a.m. ET (9:45 a.m. CT). Surmodics will also host virtual one-on-ones with investors on Wednesday, January 19, 2022. To register for the presentation or one-on-ones, visit www.sidoti.com/events.

About Surmodics, Inc.

Surmodics is a leading provider of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing development and commercialization of highly differentiated medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. This key growth strategy leverages the combination of the Company’s expertise in proprietary surface technologies, along with enhanced device design, development, and manufacturing capabilities. The Company mission remains to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota. For more information, visit www.surmodics.com. The content of Surmodics’ website is not part of this press release or part of any filings that the company makes with the Securities and Exchange Commission (“SEC”).

About Sidoti & Company, LLC

For over two decades, Sidoti has been a premier provider of independent securities research focused specifically on Small Cap and Microcap companies and the institutions that invest their securities, with most of our coverage in the $50 million to $3 billion market cap range. Our approach affords companies and institutional clients a combination of high-quality research, a Small Cap and Microcap focused nationwide sales effort, and broad access to corporate management teams. We serve 500+ institutional clients in the U.S. and Canada, including many leading managers with portfolios with $200 million to $2 billion of AUM. Sidoti promotes meaningful interaction between issuers and investors in the Small Cap and Microcap space through a series of investor conferences (www.sidoti.com/events) we host each year.

Contacts

Tim Arens
952-500-7000
ir@surmodics.com

Surmodics, Inc.

NASDAQ:SRDX

Release Summary
Surmodics to Present at Sidoti & Company Virtual Investor Conference on January 19, 2022.
Release Versions

Contacts

Tim Arens
952-500-7000
ir@surmodics.com

More News From Surmodics, Inc.

Surmodics Announces FTC Does Not Intend to Appeal Denial of Injunction, Order Preventing Closing Set to Expire Today

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX) (“Surmodics” or the “Company”), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that it expects to close its previously announced acquisition (the “Merger”) of the Company by an affiliate of GTCR LLC (“GTCR”) promptly. In a joint status report filed with the United States District Court for the Northern District of Illinois (the “District Court”), the Feder...

Surmodics Announces U.S. District Court Denies Request for Preliminary Injunction to Block Proposed Acquisition by GTCR

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX) (“Surmodics” or the “Company”), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that the United States District Court for the Northern District of Illinois (the “District Court”) has denied a request by the U.S. Federal Trade Commission (the “FTC”) and certain state regulators to issue a preliminary injunction that would have prevented the Company and GTCR...

Surmodics Announces Outcomes from 160 Patients in PROWL Registry Evaluating Pounce™ Thrombectomy Platform in Treatment of Real-World Limb Ischemia Presentations

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that results from an analysis of 160 real-world patients with symptomatic infrainguinal limb ischemia from its PROWL registry study were presented on November 3rd at an industry-sponsored session at the 23rd Annual VIVA Conference in Las Vegas, NV. PROWL national co-principal investigators Dr. Sean Lyden and...
Back to Newsroom